Kathryn is a genetic and molecular epidemiologist. Her research focuses on identifying risk factors and predictors of prostate cancer development and progression. She currently is performing large-scale studies to identify genes and genetic variants that can distinguish indolent from lethal prostate cancer at diagnosis. She is particularly interested in combining different types of data, such as genetics, RNA and protein expression, and other biomarkers, to create a more comprehensive picture of the biology of prostate cancer incidence and progression. To this end, she is working to explore the relationship between known prostate cancer risk variants with genome-wide expression levels from prostate cancer tissue. She is also further exploring results obtained developing a mRNA molecular signature of Gleason grade using tumor and sera metabolomic data.